Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity.
The effect of interleukin (IL)-18 on osteoclastic bone-resorbing activity was investigated in vitro. Osteoclast-enriched cells, about 70% of which were tartrate-resistant acid phosphatase (TRAP)-positive, were cultured on dentine slices, and then the total volume of resorption pits on each dentine slice was measured as bone-resorbing activity. When the effects of IL-18 alone at 1, 10, 100, and 1000 ng/mL were examined, bone-resorbing activity was significantly reduced only at 1000 ng/mL, by about 50%. However, IL-18 plus IL-12 (10 ng/mL each) reduced bone-resorbing activity by about 70%, whereas IL-12 alone had no significant effect. When the concentration of interferon (IFN)-gamma in the medium was measured, IL-18 or IL-12 was found to increase it slightly, and the combination of these two cytokines synergistically increased it. The inhibitory effect of the combination of the two cytokines was completely abolished by the addition of an anti-IFN-gamma neutralizing antibody to the medium, but IFN-gamma by itself did not inhibit osteoclastic bone resorption. IL-18 alone or in combination with IL-12 did not affect the number of TRAP-positive cells in culture of osteoclast-enriched cells. Osteoclasts prepared from osteoclast-enriched cells expressed mRNAs of IL-18 receptor, MyD88, and cathepsin K. Furthermore, IL-18 receptor protein was detected on the cell surface of osteoclasts. The present results indicate that the combination of IL-18 and IL-12 synergistically inhibits osteoclastic bone-resorbing activity, suggesting that IFN-gamma participates in the mechanism underlying this inhibition.
Yamada
N
N
First Department of Pathology, Hyogo College of Medicine, Nishinomiya, Japan. ynaoko@hyo-med.ac.jp
Niwa
S
S
Tsujimura
T
T
Iwasaki
T
T
Sugihara
A
A
Futani
H
H
Hayashi
S
S
Okamura
H
H
Akedo
H
H
Terada
N
N
D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy* / Q000378:metabolism; D004357:Drug Synergism; D007371:Interferon-gamma / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D018664:Interleukin-12 / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D020382:Interleukin-18 / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C
D020382:Interleukin-18; D018664:Interleukin-12; D007371:Interferon-gamma